Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus

Clin Cancer Res. 2021 Jun 1;27(11):2979-2988. doi: 10.1158/1078-0432.CCR-20-1565. Epub 2021 Feb 1.

ABSTRACT

Cancer immunotherapy targeting immune checkpoint inhibitors shows efficacy in several human cancers, but “cold tumors” that lack immune cells are typically unresponsive. Among the potential therapeutic approaches that could “heat” or promote lymphocyte infiltration of cold tumors, oncolytic viruses have attracted interest for their lytic and immunogenic mechanisms of action. In this article, we review the use of oncolytic adenoviruses in cancer immunotherapy, with a particular focus on preclinical and clinical data of oncolytic adenovirus-triggered immune responses against tumor antigens. We also discuss parameters to consider in clinical trial design and the combination of oncolytic adenoviruses with conventional treatments or other immunotherapies.

PMID:33526422 | DOI:10.1158/1078-0432.CCR-20-1565